Terbinafine 250 mg

DRUG2 trials

Sponsors

GlaxoSmithKline, University of Rome Tor Vergata

Conditions

MycosesNail DiseasesOnychomycosisResistant Infection

Phase 1

Bioequivalence Study for Terbinafine 250 mg

CompletedNCT01772212

GlaxoSmithKlineMycoses

Start: 2011-02-24End: 2011-03-15Updated: 2017-06-22

Unknown Phase

Mycosis Culture Collection From Dermatological Isolated

Active, not recruitingNCT05482763

University of Rome Tor VergataNail Diseases, Onychomycosis, Resistant Infection

Start: 2022-07-20End: 2025-12-25Target: 200Updated: 2024-05-08